GPCR News 

March 2022 Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief Commercial Officer "SAN DIEGO –...

February 2022 "Ermium Therapeutics Announces the Formation of a Scientific Advisory Board comprising international leaders in GPCRs...

February 2022 "We are proud to announce the success of our IPO! Thank you to our shareholders, both historical and new, for their trust....

February 2022 "InterAx Biotech AG and Boehringer Ingelheim take first steps towards collaborating to unlock orphan targets leveraging...

February 2022 Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical...

February 2022 "Switzerland Today, InterAx Biotech is pleased to announce that Carola Weiss has joined the company as VP Business...

February 2022 Read more at the source #DrGPCR #GPCR #IndustryNews

February 2022 Septerna emerges with $100M to spark 'second golden age' of prolific drug target GPCR with pioneer as co-founder "Jan 27,...

January 2022 Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered...

January 2022 "Watch our CEO Tim Dyer on AlphaStreet. In his interview, Mr. Dyer provides an overview of our #allostericmodulator...

January 2022 "After securing FDA approval for Wegovy last year, Novo Nordisk is strengthening its position in the obesity space through a...

January 2022 ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated Vasculitis "SAN CARLOS,...

January 2022 "The Neurocrine Biosciences story puts into words what makes the work and people at Neurocrine Biosciences so special. It...

January 2022 "G-protein-coupled receptors’ star has been on the rise in biotech in recent years as researchers have discovered the vast...

January 2022 "We are an experienced, innovative, global team on a bold mission to improve health by creating and developing life-changing...

January 2022 Inversago Pharma Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker and Provides Strategy Update...

January 2022 "OXFORD, England--Professor Charlotte Deane, Ph.D., of the University of Oxford, has joined Exscientia as Chief Scientist of...

January 2022 "Voltaire argued, “Perfection is attained by slow degrees; it requires the hand of time.” However, in drug discovery...

January 2022 "The Neurocrine Biosciences story puts into words what makes the work and people at Neurocrine Biosciences so special. It...

December 2021 "Drug development is rarely trivial. In fact, it is often costly, frustrating, and tortuous—and more often than not it...